Search results for "subclasses"

showing 10 items of 12 documents

Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: A 6 mont…

2016

Background: Some patients experience statin-induced side effects or prefer nutraceutical approaches for the treatment of dyslipidemia. This has led to a search for alternative therapeutic approaches for dyslipidemia management. In recent studies Citrus bergamia (known as Bergamot) juice was able to reduce serum levels of lipids. Such benefit may be attributed to high amounts of flavonoids contained in Bergamot fruit juice (neoeriocitrin, neohesperidin, naringin). The aim of the present study was to fully investigate the effects of a Bergamot extract on cardio-metabolic parameters, including plasma lipids, atherogenic lipoproteins and subclinical atherosclerosis. Methods: Eighty subjects (42…

0301 basic medicinemedicine.medical_specialtyHypercholesterolemiaBergamotCarotid IMT030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineNeoeriocitrinMedicinePharmacology (medical)Prospective cohort studyNaringinOriginal ResearchLDL subclassesPharmacologyNeohesperidinbusiness.industryCholesterollcsh:RM1-950medicine.diseaseCardiovascular risklcsh:Therapeutics. Pharmacology030104 developmental biologyEndocrinologychemistryLow-density lipoproteinlipids (amino acids peptides and proteins)LDL subclassebusinessDyslipidemiaLipoprotein
researchProduct

Metabolic disorders and inflammation are associated with familial combined hyperlipemia

2019

Background: Familial Combined Hyperlipidemia (FCH) is related to different metabolic disorders. The objective of this study was to evaluate the presence of alterations of hydrocarbonated metabolism and lipid profile together with inflammatory and adhesion molecules in subjects with FCH compared to controls. Methods: 75 HFC patients and 75 healthy individuals were studied. Glucose, insulin, HOMA-IR index and lipid parameters, in addition to anti-oxidized LDL antibodies (Anti ox-LDL), small and dense LDL (sdLDL) and HDL subfractions, proinflammatory cytokines and adhesion molecules were measured. Results: FCH patients showed higher levels of hydrocarbonated metabolism parameters, total choles…

AdultMale0301 basic medicinemedicine.medical_specialtyApolipoprotein Bmedicine.medical_treatmentPhenotype B of LDL HDL subclassesClinical BiochemistryHyperlipidemia Familial CombinedInflammationBiochemistryProinflammatory cytokine03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicinemedicineHumansInflammationmedicine.diagnostic_testbiologybusiness.industryCell adhesion moleculeInsulinCholesterol HDLFCHBiochemistry (medical)Insulin resistanceGeneral MedicineMetabolismmedicine.diseasePhenotype030104 developmental biologyEndocrinology030220 oncology & carcinogenesisbiology.proteinCytokinesFemalelipids (amino acids peptides and proteins)medicine.symptombusinessLipid profileAdhesion moleculesClinica Chimica Acta
researchProduct

Serum low density lipoprotein subclasses in asthma

2013

Summary Background The levels of serum low-density lipoproteins (LDL) have been implicated in the inflammatory cascade in a murine model of asthma. Recent findings suggest that LDL may modulate the inflammatory state of the asthmatic airways in humans. Objective We explored whether LDL subclasses are associated with the occurrence and severity of asthma. Methods 24 asthmatics (M/F: 11/13) and 24 healthy individuals, with normal BMI and absence of metabolic syndrome, matched for age and gender. Serum concentrations of LDL subclasses were distributed as seven bands (LDL-1 and -2 defined as large, least pro-inflammatory LDL, and LDL-3 to −7 defined as small, most pro-inflammatory LDL), using t…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyVital CapacityAsthma pathogenesiPilot ProjectsSettore MED/10 - Malattie Dell'Apparato RespiratorioFEV1Forced Expiratory VolumeInternal medicineStatistical significanceAsthma pathogenesisHumansMedicineAgedAsthmaLDL subclassesAged 80 and overDyslipidemia; Asthma pathogenesis; FEV1; LDL subclassesbusiness.industryMiddle AgedSerum concentrationHypolipoproteinemiasmedicine.diseaseAsthmaLipoproteins LDLEndocrinologyDyslipidemiaMurine modelInflammatory cascadeFemaleSerum low density lipoproteinlipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaRespiratory Medicine
researchProduct

Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with growth hormone deficiency before and after short-term replacement ther…

2007

Atherogenic lipoprotein LDL size and subclasses growth hormone replacement therapy
researchProduct

Impact of a Three Amino Acid Deletion in the CH2 Domain of Murine IgG1 on Fc-Associated Effector Functions

2008

Abstract Four murine IgG subclasses display markedly different Fc-associated effector functions because of their differential binding to three activating IgG Fc receptors (FcγRI, FcγRIII, and FcγRIV) and C1q. Previous analysis of IgG subclass switch variants of 34-3C anti-RBC monoclonal autoantibodies revealed that the IgG1 subclass, which binds only to FcγRIII and fails to activate complement, displayed the poorest pathogenic potential. This could be related to the presence of a three amino acid deletion at positions 233–235 in the CH2 domain uniquely found in this subclass. To address this question, IgG1 insertion and IgG2b deletion mutants at positions 233–235 of 34-3C anti-RBC Abs were …

Deletion mutantImmunologyAntibody AffinityDown-Regulationddc:616.07BiologySubclassProtein Structure Tertiary/geneticsMiceAnimalsImmunology and AllergyAmino AcidsEffector functionsSequence DeletionMice Knockoutchemistry.chemical_classificationMice Inbred BALB CMice Inbred NZBAnemia Hemolytic Autoimmune/genetics/immunologyReceptors IgGAutoantibodyAmino Acids/chemistry/genetics/metabolismIgg subclassesReceptors IgG/antagonists & inhibitors/genetics/metabolismPathogenicityProtein Structure TertiaryImmunoglobulin G/genetics/metabolismImmunoglobulin Switch RegionCell biologyAmino acidImmunoglobulin Heavy Chains/biosynthesis/genetics/metabolismAntibody Affinity/geneticsBiochemistrychemistryImmunoglobulin GMonoclonalMutagenesis Site-DirectedAnemia Hemolytic AutoimmuneDown-Regulation/genetics/immunologyImmunoglobulin Heavy ChainsThe Journal of Immunology
researchProduct

"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL sub…

2011

Item does not contain fulltext

ElectrophoresisHealth aging / healthy living [IGMD 5]Magnetic Resonance SpectroscopyLDL subclasses atherosclerosis cardiovascular risk10265 Clinic for Endocrinology and Diabetology610 Medicine & healthAtherosclerosis2705 Cardiology and Cardiovascular MedicineLipoproteins LDL3004 PharmacologyAnimalsHumansClinical MedicineLife StyleUltracentrifugationMonitoring Physiologic
researchProduct

Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes

2010

Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbA1c] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased …

Malehigh-density lipoproteinsmedicine.medical_specialtyType 2 diabetes030204 cardiovascular system & hematologysizeStatistics NonparametricRosiglitazone03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicinelow-density lipoproteinsHumansHypoglycemic AgentsProspective Studies030212 general & internal medicineGlycated Hemoglobindiabetesbusiness.industryFastingMiddle AgedPostprandial Periodmedicine.diseaseLipids3. Good healthLipoproteins LDLPostprandialEndocrinologyDiabetes Mellitus Type 2FemaleThiazolidinedioneslipids (amino acids peptides and proteins)HemoglobinsubclassesLipoproteins HDLCardiology and Cardiovascular MedicineRosiglitazonebusinessPioglitazoneDyslipidemiamedicine.drugLipoprotein
researchProduct

The effects of anti-diabetic drugs on LDL subclasses: any role for colesevelam?

2014

anti-diabetic drugs LDL subclasses colesevelam.
researchProduct

European Panel on Low Density Lipoprotein (LDL) Subclasses: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subcl…

2011

Item does not contain fulltext Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL) subclasses. We sub-divided our statement in 2 sections. section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drug and lifestyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.

cardiovascular riskischemic-heart-diseaseHealth aging / healthy living [IGMD 5]coronary-artery-diseaseapolipoprotein-b metabolismcholesteryl ester transferAtherosclerosisstatementfamilial combined hyperlipidemialdlLipoproteins LDLvery-low-densitynuclear-magnetic-resonancec-reactive proteinRisk FactorsAnimalsHumansGenetic Predisposition to DiseaseLDL subclasses atherosclerosis cardiovascular risk statementsubclassesatherosclerosistype-2 diabetes-mellitusintima-media thickness
researchProduct

Should we routinely measure low-density and high-density lipoprotein subclasses?

2009

Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) plasma populations are composed of heterogeneous subfractions that are different in size, density and protein/lipid content. There is increasing evidence that small, dense LDL particles are strongly associated with higher cardiovascular disease risk. Similarly, several studies have investigated whether smaller HDL particles are more protective than their larger counterparts and more recent findings suggest that small, dense HDL has significantly higher atheroprotective activity than larger L HDL. Yet, certain impairments of the protein/lipid content in small, dense HDL may decrease its antiatherogenic capacity or even induce p…

lipoproteinscardiovascular riskHDLlipids (amino acids peptides and proteins)subclassesaterosclerosiLDL
researchProduct